SPRK

[Benjamin Howard @BenHowardOPT]

Lowest FTA differential in the playoffs:

1) Minnesota Timberwolves - -54
2) Phoenix Suns - -20
3) Houston Rockets - -11
4) Portland Trail Blazers - -11
5) Toronto Raptors - -5

[BioBoyScout @BioBoyScout]

BIIB080 floods the cortex but barely reaches the hippocampus.
$ARWR ARO-MAPT goes subcutaneous through the transferrin receptor and hits the deep brain uniformly.
Same target. Better real estate.
New paper on the 2H2026 readout setup, now on Substack:
https://t.co/H6Kz4QQz9e

[zohm @zohmbastic]

$VLN

[HODOR @Maximus_Holla]

$MLYS 30 then 31.49!

[SPRK @poolflips]

@Jabs_13 He actually had some great opportunities to make plays. But he has developed tunnel vision for flopping and injuring ppl

[BioBoyScout @BioBoyScout]

$ARWR trades at over $10B today.
If ARO-MAPT's Phase 1 reads positive in 2H 2026, the math says it's worth $55-$90B to a strategic acquirer.
Not a guess. Four independent methodologies. Same range.
Full paper: https://t.co/0PnxQiLnzP

[zohm @zohmbastic]

$mlys

[zohm @zohmbastic]

$RLMD

[Sam Richards @MinneapoliSam]

Minnesota wins again. Quality of life and affordability metrics top the chart-- all nine measured beat the national average.

[zohm @zohmbastic]

$MLYS Ra some size ~$8.76M worth at ~23.75 https://t.co/aIXdvl1WlJ

[zohm @zohmbastic]

$OMER Omeros Q4 Adj. EPS $3.14 Beats $(0.57) Estimate

[mr_eggs @scrumble_eggs]

I’ve pooped in toilets you wouldn’t even piss in.

[zohm @zohmbastic]

$RCKT approval

[zohm @zohmbastic]

$OUST

[Team USA @TeamUSA]

Fifty states. One podium. 🇺🇸

Team USA’s medal haul spans the map.

#WinterOlympics

[Clemente @Chilearmy123]

Interstellar but Cooper's son is the worst trader of all time

[Wild trading @YYDSxjm]

$IOVA
has 4 big near-term catalysts that could ignite serious upside:

Tandem Meetings 2026 Real-World Data Drop
New real-world evidence on Amtagvi in advanced melanoma (building on strong ~49% ORR commercial data).

Q4 2025 Earnings + 2026 Guidance
Expected Feb 26, 2026. With 2025 revenue guidance reaffirmed at $250-300M and >1,000 patients treated, look for accelerating sales, margin gains from in-house manufacturing, and potentially upbeat 2026 outlook to spark a rally.

Endometrial Cancer Results (IOV-END-201)
Initial data from Phase 2 in advanced endometrial cancer (post-PD-1) on track for early 2026. Huge unmet need—no approved options here—positive readout could unlock a new major indication and expand the platform massively.

IOV-4001 (PD-1 Knockout TIL) Results
Clinical results in previously treated advanced melanoma expected Q1 2026. This next-gen engineered TIL could show boosted efficacy over standard—

[zohm @zohmbastic]

$IOVA interesting March 3.5c flow today

[Jason Bassler @JasonBassler1]

Two cults. One mantra. Zero critical thinking.

[BioBoyScout @BioBoyScout]

1/3 $ARWR just priced financing at an institutional premium, not a fire sale. Zero-interest convertible notes at a meaningful premium plus a modest equity raise locks in years of runway. That structure matters.